Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ghassan Al-Sabbagh

Gastroenterology Wake Forest, NC Medical Doctor

NPI 1487617858 CMS profile 747304

10540 Ligon Mill Rd Ste 109, Wake Forest, NC 27587

Open in the dashboard

General payments

$8,118

467 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ghassan Al-Sabbagh of Wake Forest, NC is reported in the CMS Open Payments database as having received $8,118 across 467 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,460 78
2024 General $1,580 82
2023 General $1,517 83
2022 General $1,483 87
2021 General $942 60
2020 General $377 23
2019 General $758 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ghassan Al-Sabbagh
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Ghassan Al-Sabbagh were reported at $1,460. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Ghassan Al-Sabbagh Gastroenterology median Middle half National median
2019 $758 $417 $126–$1,100 $163
2020 $377 $224 $74–$624 $114
2021 $942 $352 $106–$1,054 $132
2022 $1,483 $448 $129–$1,270 $149
2023 $1,517 $533 $150–$1,390 $160
2024 $1,580 $605 $160–$1,606 $164
2025 $1,460 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,190 148 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $857 50 payments
  3. Gilead Sciences, Inc. $751 40 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $702 43 payments
  5. Intercept Pharmaceuticals, Inc. $371 21 payments
  6. Pfizer Inc. $368 20 payments
  7. Ardelyx, Inc. $351 19 payments
  8. Janssen Biotech, Inc. $340 16 payments
  9. QOL Medical, LLC $317 16 payments
  10. Merck Sharp & Dohme Corporation $217 13 payments
  11. Other $1,654 81 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,085 465 payments
  2. Education $33 2 payments
Products named General payments · program years 2019–2025
  1. MAVYRET $678 47 payments
  2. RINVOQ $622 40 payments
  3. LINZESS $542 36 payments
  4. CREON $478 32 payments
  5. XIFAXAN $445 24 payments
  6. ENTYVIO $373 23 payments
  7. IBSRELA $351 19 payments
  8. XELJANZ $335 18 payments
  9. OCALIVA $325 18 payments
  10. SKYRIZI $324 19 payments
  11. Other $4,338 231 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,864

Median for Internal Medicine: 777

Drug cost

$317,688

Median for Internal Medicine: $73,373

Branded share of claims

32.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 150 $123,849
Ocaliva Obeticholic Acid Brand 12 $110,791
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 358 $24,211
Mesalamine Generic 21 $17,237
Budesonide Er Budesonide Brand 11 $11,384
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 30 $5,106
Sucralfate Generic 67 $4,698
Famotidine Generic 246 $3,500
Mesalamine Er Mesalamine Brand 15 $3,107
Omeprazole Generic 251 $2,653

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$74,982

Medicare's payments for the services billed

Medicare patients

340

Average age 73

Services billed

795

200 women, 140 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 29%
Ischemic heart disease 27%
Depression 26%
Chronic kidney disease 24%
Cancer 20%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $132
$132 — —
RINVOQ
  • AbbVie, Inc. $109
$109 — —
MAVYRET
  • AbbVie, Inc. $94
$94 — —
IBSRELA
  • Ardelyx, Inc. $93
$93 — —
LINZESS
  • AbbVie, Inc. $63
  • Ironwood Pharmaceuticals, Inc $21
$85 150 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

467 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record